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Abstract 
The most common site for localized forms of plasma cell neoplasms (extramedullary 
plasmacytoma; EMP) is the upper respiratory tract, including the oropharynx, nasal cavities, 
sinuses and larynx. A 50-year-old woman with a history of myeloma in complete remission 
after autologous stem cell transplantation complained of two weeks of epiphora of the left 
eye with subsequent diplopia, bloody nasal discharge and progressive swelling around the 
nasolacrimal sac. A solitary mass in the left sinonasal area, extending to the nasolacrimal 
duct (NLD) was detected on MRI, whose histopathological examination was consistent with 
plasmacytoma. Further clinical investigation ruled out multiple myeloma (MM). The patient 
underwent debulking surgery and adjuvant chemotherapy followed by local radiotherapy in 
an attempt to achieve complete response. Despite being a rare entity, EMP of the NLD 
should be considered in the differential diagnosis of epiphora and dacryocystitis. To our 
knowledge, this is the first case of a plasmacytoma of the NLD presenting as isolated 
extramedullary relapse of MM. The follow-up in EMPs should include appropriate imaging 
studies, a systemic workup to rule out MM. 
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Introduction 
Congenital or acquired nasolacrimal duct (NLD) obstruction is the most common 
abnormality of the lacrimal drainage system. NLD obstruction may be primary or 
secondary to infection, inflammation, neoplasm, trauma or mechanical causes. The 
mechanical obstruction of NLD by a plasmacytoma is rare. Herein, we report a 50-year-
old female patient who had presented with epiphora of the left eye and been treated 
initially as dacryocystitis. Distention of the lacrimal sac secondary to NLD obstruction 
was detected by imaging MRI. Histopathologic examination revealed plasma cell 
infiltration. 
Case Presentation 
A 50-year-old woman with a history of multiple myeloma (MM) in complete remission after high-
dose chemotherapy with autologous stem cell rescue was admitted with swelling and overtearing of 
the left eye. With the prediagnosis of NLD obstruction, dacryoscintigraphy was planned. In two weeks, 
erythema and swelling around the left eye and nose became evident. Antimicrobial therapy for one 
week was given with suspicion of dacryocystitis. Yet, the symptoms progressed with additional 
symptoms of diplopia and bloody discharge from left nose (fig. 1). MRI of the orbit and paranasal 
sinuses revealed a 3 × 5 × 7.5 cm mass in the left sinonasal area infiltrating the left anterior, medial, 
posterior ethmoidal sinuses, left nasal cavity, left maxillary sinus, left orbit, left soft and hard palates 
and displacing the left globe laterally. The mass also extended to the NLD, the left pterygomaxillary 
fossa, infratemporal fossa and middle cranial fossa (fig. 2). Excisional biopsy of the paranasal sinus 
revealed diffuse CD38-positive plasma cell infiltration with kappa light chain restriction (fig. 3). On 
serum protein electrophoresis, a monoclonal protein of 0.01 g/dl was present and immunofixation 
electrophoresis in serum and urine showed the same amount of paraproteinemia as at the time of 
initial diagnosis as MM. Serum kappa light chain levels were increased (882 mg/l). Serum albumin 
and beta 2-microglobulin levels were normal; serum LDH level was slightly increased. The final 
diagnosis was extramedullary relapse of MM. High-dose steroid was given as urgent treatment 
followed by debulking surgery including left maxillectomy, resection of the inferior orbital wall and a 
portion of the soft and hard palates. Histopathologic examination of the surgical material showed 
diffuse plasma cell infiltration (fig. 4). On postoperative orbital MRI, a 2.5 × 2 cm residual mass in the 
left medial pterygoid muscle was present. One month after the surgery, allergic reaction developed 
against the prosthetic support material placed under the orbit resulting in orbital displacement. 
Hence, the remission induction chemotherapy was postponed. The prosthesis was removed. Biopsy 
sample from the orbital soft tissue showed granulation tissue, fibrosis and foreign body reaction. 
Radiotherapy was also postponed in anticipation for delay in wound healing. Two months later, 
orbital reconstruction was made by forehead flap. At that time, serum kappa light chain decreased to 
109 mg/l. Salvage chemotherapy with bortezomib, cyclophosphamide and dexamethasone for three 
courses was given. Three months later, radiotherapy at 36 Gy in 18 fractions was performed to the 
postoperative residual tissue at the left mastoid region. 
Discussion 
Plasma cell neoplasms are a group of entities characterized by the neoplastic 
proliferation of a single clone of plasma cells, typically producing a monoclonal 
immunoglobulin. Plasma cell tumors can manifest as a single lesion (solitary 
plasmacytoma) or as multiple lesions (MM). Solitary plasmacytomas most frequently 
originate from bone (plasmacytoma of bone) or arise in soft tissues as mass lesions 
(extramedullary plasmacytoma; EMP) [1, 2]. EMPs, which account for approximately 3 
percent of plasma cell malignancies, are most often located in the upper respiratory 
tract, including the oropharynx, nasal cavities, sinuses and larynx while the bone  
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plasmacytoma frequently presents in the axial skeleton [3–5]. EMPs often present with 
signs or symptoms related to mass effect. Approximately 80 percent involve the upper 
respiratory tract (i.e., oronasopharynx and paranasal sinuses) causing epistaxis, nasal 
discharge (rhinorrhea), or nasal obstruction [6–9]. Orbital tumors are uncommon and 
often present with nonspecific findings mimicking the symptoms of dacryocystitis. EMP 
of the orbit is an even rarer entity with only a few cases reported to date [10]. Imaging 
features of EMPs are nonspecific. Histopathological examination differentiates these 
tumors from more common malignant entities such as natural killer cell lymphoma, 
squamous cell carcinoma, adenocystic carcinoma, rhabdomyosarcoma or metastasis 
from other primaries [11]. Systemic involvement must be ruled out by clinical, 
biochemical, hematological and radiological modalities both at the time of initial 
diagnosis and during follow-up. 
The primary method of treatment of EMP is radiation therapy. The treatment of 
choice is external beam radiation at doses ranging from 4,000 to 6,000 cGy 
administered over 5 to 7 weeks. The role of surgery is generally limited to open biopsy 
for diagnosis or for debulking a large tumor. Complete excision of EMP is often difficult 
due to the close proximity to vital structures and large tumor size. Surgery can often 
cause significant functional and cosmetic deformity. The rate of local control for EMPs 
following treatment with radiotherapy or surgery is 75% to 95% [12]. In our case, 
adjuvant chemotherapy was administered in addition to local therapy to achieve 
complete response for extramedullary relapse of myeloma. Following completion of 
therapy, patients should be monitored for treatment complications and for possible 
relapse every 3 months for the first two years, every 6 months for an additional three 
years and every 1 or 2 years. A detailed history and physical examination as well as 
laboratory parameters including a complete blood count, serum creatinine, and 
calcium, serum and urine protein electrophoresis with immunofixation are required at 
each visit. If the extent of an EMP had been measured by an imaging modality prior to 
therapy, the same modality (e.g., MRI) should be repeated three to four months after 
completing therapy, and periodically thereafter. 
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Fig. 1. Left eye swelling extending to the left side of the nose accompanied by bloody nasal discharge. 
 
 
 
Fig. 2. MRI revealed a 3 × 5 × 7.5 cm mass in the left sinonasal area extending to the nasolacrimal 
duct (marked with arrow). 
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Fig. 3. Plasma cell infiltration within the mucosal glands (a, H&E, ×400), the infiltrating cells positive 
for CD38 (b, ×400) and kappa light chain (c, ×400), and negative for lambda light chain (d, ×400). 
 
 
 
Fig. 4. Plasma cell infiltration underneath the surface epithelium in maxillary sinus (a, H&E, ×400; 
b, H&E, ×600). 
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